Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.

Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. We conducted a multicenter, double-blind, phase 3 ...

More patients with eosinophilic esophagitis experienced a histologic response with benralizumab (Fasenra) compared with placebo, despite similar levels of continuing symptoms in the two groups at ...

The safety of benralizumab showed no “meaningful difference” compared with mepolizumab. Benralizumab only requires one monthly injection, while mepolizumab requires three. Benralizumab is ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

Benralizumab injections reduce exacerbations in severe, uncontrolled asthma, according to two trials Date: September 5, 2016 Source: The Lancet Summary: A year's course of benralizumab injections ...

--(BUSINESS WIRE)--Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care ...

31% of patients taking benralizumab and 33% of those taking mepolizumab also used daily oral corticosteroids. Most exacerbations occurred within 5 months of treatment. BOSTON — Patients taking ...

Benralizumab, an interleukin-5 (IL-5) antagonist used to treat severe asthma, does not weaken antibody response of influenza vaccinations, according to results of a recent study. Benralizumab ...

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General ...

After three months of treatment, four times fewer people taking benralizumab had suffered an asthma or COPD attack, compared to people taking the steroid prednisolone. “This could be a game ...